Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05287477
Other study ID # 20HH6297
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 24, 2022
Est. completion date August 31, 2024

Study information

Verified date October 2023
Source Imperial College London
Contact Anthony C Gordon
Phone 02033126328
Email anthony.gordon@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sepsis, or systemic infection, is a common reason for ICU admission and death throughout the world. Despite advances in the way we treat this condition, it remains a significant economic and healthcare burden. A key part of the treatment of sepsis is the administration of IV fluids and blood pressure medication. However, there is huge uncertainty around dosing of these drugs in an individual patient. A tool to personalise these medications could improve patient survival. The study team has developed a new method to automatically and continuously review and recommend the correct medication doses to doctors, which was created using artificial intelligence (AI) techniques applied to large medical databases. The researchers' previous work has shown it has the potential to improve patient survival rates. The tool will be capable of processing patient data within the electronic patient record of NHS hospitals in real-time to suggest a course of action. This tool will be evaluated and refined in simulation studies and then be tested in two NHS Trusts in "shadow mode" (results not provided to duty clinicians). This will allow comparison of actual decisions made and recommended decisions from the AI system. The second stage of this clinical evaluation will display the recommendations to clinicians to assess the acceptability of the tool and confirm technical feasibility to inform future clinical trials. The long-term expected benefits of this project are numerous: improved patient survival, reduced use of precious intensive care resources and reduction in healthcare costs.


Description:

Sepsis is life-threatening organ dysfunction due to severe infection and affects 250,000 patients annually in the UK (pre-COVID-19), of whom 48,000 die. In addition, virtually all COVID-19 intensive care unit (ICU) deaths had sepsis. It is a leading cause of death and the most expensive condition treated in hospitals. It was recognised as a top research priority by the James Lind Alliance, a partnership of patients and clinicians to prioritise the most pressing unanswered questions facing the NHS. The cornerstone of sepsis resuscitation is the administration of intravenous fluids and/or vasopressors (drugs that squeeze the blood vessels to increase blood pressure) to maintain blood flow to prevent organ failure. However, there is huge uncertainty around the individual dosing of these drugs in an individual patient, partially due to high sepsis heterogeneity. The current guidelines provide recommendations at a population-level but fail to individualise the decisions. Wrong decisions lead to poorer outcomes and increased ICU-resource use. A tool to personalise these medications could improve patient survival. The study team has developed a new method to automatically and continuously review and recommend the correct dose of these medications to doctors, which was created using artificial intelligence (AI) techniques applied to large medical databases. The method used is called reinforcement learning. In this framework, the study models patients with sepsis in the ICU as belonging to a large number of possible disease states, and analyses what interventions are likely to help them transition to healthier states, and eventually to survival. The researchers demonstrated in their initial publication that the value of the AI selected strategy was on average reliably higher than human clinicians. In a large validation cohort independent from the training data, mortality was lowest in patients where clinicians' actual doses matched the AI decisions: mortality rates rose, in a dose dependent manner, as the clinicians' actual decisions diverged from the AI decisions. The study team has estimated that their AI algorithm could reduce mortality by 10% (in relative terms), which represents over 1,000 lives saved annually in the UK and would scale to hundreds of thousands of lives worldwide. Now, the study team intends to start clinical testing of this AI technology in the UK. The envisioned end-product will be a piece of software that will be accessible by clinicians (ICU doctors initially, then eventually to ICU nurses as well) at the bedside in intensive care. This software will be connected to the electronic patient record, which will be fed to the AI algorithm. In return, the AI will identify where the patient sits in the array of possible disease states, and which actions (a dose of intravenous fluids and vasopressors) are most likely to be beneficial. First, the study team will develop this software tool, capable of processing patient data within the electronic patient record of NHS hospitals in real-time to suggest a course of action. The study will start by evaluating and refining this tool in simulation studies. The study team will then test the AI tool in two NHS Trusts in a "shadow mode" when the result is not provided to duty clinicians in charge of patient care. This will allow comparison of actual decisions made and recommended decisions from the AI system. In the second stage of the clinical evaluation, the study team will display the recommendations to clinicians to assess the acceptability of the tool to clinicians and also confirm the technical feasibility to inform future large scale clinical trials. The long-term expected benefits of this project are numerous: improved patient survival, reduced use of precious intensive care resources and reduction in healthcare costs.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For patients: - Adult patient > 18 years old - Admitted to an intensive care unit - Likely or confirmed diagnosis of sepsis as per sepsis-3 definition (as defined in the glossary) - ICU length of stay > 24h For Evaluators: - ICU doctors at the senior registrar, ICU fellow or consultant level Exclusion Criteria: For patients: - Not for full active care, e.g. not for vasopressors - Not expected to survive more than 24h - Elective surgical admission (these patients are regularly on antibiotics but given as a prophylaxis, with no sepsis) - Opted-out for use of their data for research (NHS and NHS-X website) For both patients and evaluators: Declined participation No patient consent is required

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Imperial College Hospitals NHS Trust London
United Kingdom Univeristy College London Hospitals NHS Foundation Trust London

Sponsors (2)

Lead Sponsor Collaborator
Imperial College London National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Data Availability Data availability: what percentage of essential and optional data fields are available 24/7. 18 months
Primary Anonymised patients' data Patient demographics (age in years, gender, primary diagnosis) Outcomes: organ function (hourly SOFA), ICU and hospital mortality 18 months
Primary Rate of intravenous fluids administered to patients Rate of intravenous fluids (millilitres per hour) and vasopressors (noradrenaline equivalent, in micrograms per kilogram per minute) administered to patients. 18 months
Primary Evaluators' data (the doctors assessing the AI in the background) The evaluator's grade and seniority (i.e.
A custom-made interface linked to a database will capture and record the following:
What rate of intravenous fluids (millilitres per hour) and vasopressors (noradrenaline equivalent, in micrograms per kilogram per minute) they would recommend, before and after seeing the AI suggested dose.
Agreement with the AI suggested dose on a Likert scale including the following labels: "the AI suggested dose is:" "certainly too low", "possibly too low","likely appropriate","possibly too high", "certainly too high".
After collecting this data, we will report the median difference (with interquartile range) between the AI suggested doses and the evaluator suggested doses, as well as the proportion of AI decisions in each agreement category ("certainly too low", "possibly too low","likely appropriate","possibly too high", "certainly too high").
18 months
Primary System Availability System availability: delays in generating response 24/7. Number and nature of technical issues (drop-outs, freezes). 18 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3